Is there a role for antiplatelet therapy in infective endocarditis? A review of current scientific evidence.
Recently, interest has emerged regarding adjuvant antiplatelet therapy in infective endocarditis (IE) and its impact on clinical outcomes. Despite ongoing research, the role of antiplatelet therapy in this setting remains unclear. Generally, investigations of IE are limited by the low incidence of the disease, practical issues related to diagnosis, and the highly variable latency period between symptom onset and definitive diagnosis. This article reviews the rationale for using antiplatelet therapy in the setting of IE and the contemporary literature that investigates its use.